Benefits of the Topical JAK Inhibitor Delgocitinib in a Patient With Pediatric Localized Scleroderma
Pediatric Dermatology · 2025
DOI: 10.1111/pde.15844 ↗Kurz gefasst
Fallbericht in der Zeitschrift Pediatric Dermatology, 2025. Verfasst von Mayuko Yamamoto und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology, Kochi Medical School, Kochi University, Kochi, Japan. Hauptthemen laut MEDLINE: Janus Kinase Inhibitors, Scleroderma, Localized. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 5 Literaturangaben.
Abstract (Originalsprache)
This is the first report of pediatric linear scleroderma successfully treated with the topical Janus kinase (JAK) inhibitor delgocitinib. JAK inhibitors targeting the JAK/STAT pathway have been used to treat various immune‐mediated diseases. In both in vitro and in vivo, JAK inhibitors also block the transforming growth factor (TGF)‐β‐mediated effects that contribute to skin sclerosis. In the present case, the histological findings of inflammation and fibrosis were considered as conditions that would benefit from the anti‐inflammatory and antifibrotic effects of the JAK inhibitor, delgocitinib.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Dermatology, Kochi Medical School, Kochi University, Kochi, Japan.
- Department of Dermatology, Graduate School of Medical, Dentistry and Pharmaceutical Sciences, Okayama University, Okayama, Japan.
ORCID-Profile: Mayuko Yamamoto
Zitieren
APA
Yamamoto, M., Nakajima, K., Matsuda, M., Takahashi, A., & Nakai, K. (2025). Benefits of the Topical JAK Inhibitor Delgocitinib in a Patient With Pediatric Localized Scleroderma. Pediatric Dermatology. https://doi.org/10.1111/pde.15844
Vancouver
Yamamoto M, Nakajima K, Matsuda M, Takahashi A, Nakai K. Benefits of the Topical JAK Inhibitor Delgocitinib in a Patient With Pediatric Localized Scleroderma. Pediatric Dermatology. 2025. doi:10.1111/pde.15844
BibTeX
@article{Yamamoto2025,
author = {Yamamoto, Mayuko and Nakajima, Kimiko and Matsuda, Mayuko and Takahashi, Aya and Nakai, Kozo},
title = {Benefits of the Topical JAK Inhibitor Delgocitinib in a Patient With Pediatric Localized Scleroderma},
journal = {Pediatric Dermatology},
year = {2025},
doi = {10.1111/pde.15844}
}
EUVIMED